{
    "clinical_study": {
        "@rank": "26670", 
        "arm_group": [
            {
                "arm_group_label": "Oral misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery."
            }, 
            {
                "arm_group_label": "Sublingual misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery."
            }, 
            {
                "arm_group_label": "Vaginal misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "The no-misoprostol group did not administer the medication of misoprostol before the procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the efficacy of oral, sublingual, vaginal, and no\n      misoprostol prior to operative hysteroscopy in  premenopausal women."
        }, 
        "brief_title": "Misoprostol Administration Before Operative Hysteroscopy", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Endometrial Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Endometriosis", 
                "Endometritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The route of administration of misoprostol for cervical dilatation prior to operative\n      hysteroscopy can be oral, vaginal, or sublingual. However, it is still unclear which route\n      is more effective and less harmful for cervical dilation prior to operative hysteroscopy in\n      premenopausal women. Furthermore, there have been no studies comparing among oral,\n      sublingual, and vaginal misoprostol, no medication (control) in these women. The objective\n      of this study is to compare the efficacy and safety of oral, sublingual, vaginal, and no\n      misoprostol prior to operative hysteroscopy in premenopausal women."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Symptomatic patients that were suspected as having intrauterine pathology, such as\n        submucosal myoma, endometrial polyp or other endometrial pathological findings based on\n        the transvaginal ultrasound, were enrolled.\n\n        Inclusion criteria were as follows: women who were of reproductive age (i.e., were\n        premenopausal) and were not pregnant at the time of presentation (i.e., negative for urine\n        pregnancy test or last menstrual period within the last 4 weeks).   -\n\n        Exclusion Criteria:\n\n        Exclusion criteria included any evidence of a contraindication to prostaglandins (history\n        of severe asthma, glaucoma, preexisting severe cardiac disease, or renal failure), or\n        allergy to prostaglandins, any sign of genital infection, presence of significant\n        uterovaginal prolapse that could affect administration of vaginal tablets, history of\n        cervical surgery, presence of space occupying lesions in endocervical canal, and treatment\n        of GnRH agonist."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805115", 
            "org_study_id": "KNC13-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oral misoprostol", 
                "description": "Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 \u03bcg of misoprostol (two tablets of Cytotec; 200 \u03bcg). All misoprostol tablets were identical and patients were blinded to group allocation", 
                "intervention_name": "Oral misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "two tablets of Cytotec (200 \u03bcg)"
            }, 
            {
                "arm_group_label": "Sublingual misoprostol", 
                "description": "Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 \u03bcg of misoprostol (two tablets of Cytotec; 200 \u03bcg). All misoprostol tablets were identical and patients were blinded to group allocation", 
                "intervention_name": "Sublingual misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "two tablets of Cytotec (200 \u03bcg)"
            }, 
            {
                "arm_group_label": "Vaginal misoprostol", 
                "description": "Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 \u03bcg of misoprostol (two tablets of Cytotec; 200 \u03bcg). All misoprostol tablets were identical and patients were blinded to group allocation", 
                "intervention_name": "Vaginal misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "two tablets of Cytotec (200 \u03bcg)"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "The control group was not given any cervical priming agents or placebo.", 
                "intervention_name": "Control", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Misoprostol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hysteroscopy", 
            "misoprostol"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "taejong.song@gmail.com", 
                "last_name": "Taejong Song, MD", 
                "phone": "+82-2-3468-3032"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-081"
                }, 
                "name": "CHA Gangnam Medical Center"
            }, 
            "investigator": {
                "last_name": "Taejong Song, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Comparison of Oral, Sublingual and Vaginal Misoprostol Administration in Premenopausal Women Before Operative Hysteroscopy", 
        "overall_contact": {
            "email": "taejong.song@gmail.com", 
            "last_name": "Taejong Song, MD", 
            "phone": "+82-2-3468-3032"
        }, 
        "overall_official": {
            "affiliation": "Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea", 
            "last_name": "Taejong Song, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure was the preoperative cervical width at the time of operation. The cervical width was assessed by performing cervical dilation, starting with a number 10 Hegar dilator and subsequently inserting smaller Hegar dilators until dilator could pass through the internal os without resistance. The largest one that could be passed was recorded as the initial cervical width.", 
            "measure": "the preoperative cervical width", 
            "safety_issue": "No", 
            "time_frame": "just before the operation (From finish of anesthesic induction to introduction of a rigid resectoscope with 10-mm outer sheath diameter in uterine cavity)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805115"
        }, 
        "responsible_party": {
            "investigator_affiliation": "CHA University", 
            "investigator_full_name": "Taejong Song", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "misoprostol-associated side effects", 
            "safety_issue": "Yes", 
            "time_frame": "before the procedures"
        }, 
        "source": "CHA University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CHA University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}